SoftBank Vision Fund is a subsidiary of Softbank Group that specializes in growth capital and social impact investments. Sectors that the fund invests in include the internet of things, artificial intelligence (AI), robotics, communications infrastructure, telecoms, computational biology, biotech, cloud technologies and software, consumer internet businesses, financial technology, and mobile apps. The Fund is designed to be a catalyst for technology progress in anticipation that it will expand SoftBank's capabilities, accelerating progress towards SoftBank 2.0. It aims to invest in businesses and foundational platforms that SoftBank believes to revolutionize and innovate the world tomorrow.

SoftBank Vision Fund

Prosperity7 Ventures is a venture capital firm that invests in early and growth-stage startups with a long-term view. The firm investments range from early-stage enterprise, blockchain, financial and industrial technologies to medical and healthcare solutions. industries as diverse as MedTech, fintech, and B2B SaaS. They provide venture funding that presents an unparalleled opportunity for international scalability and impact.

Prosperity7 Ventures

Founded in 2001, Tiger Global Management, LLC (“Tiger Global”) is a New York-based investment firm pursuing a long-term approach to investing in leading, global public and private companies that leverage technological innovation. Tiger Global’s public equity business includes fundamentally oriented long/short, long-focused and crossover strategies, targeting investments in high-quality, public growth companies. The private equity business invests in early through late stage companies that pursue innovative approaches to new and existing industries, building on over 20 years of experience investing in hundreds of businesses in more than 30 countries with more than 90 portfolio company IPOs. With a strong track record investing across sectors and stages, Tiger Global aims to be a thought partner to companies and their management teams across their lifecycle in public and private markets. The Firm’s mission is to generate world-class returns for its investors and to do so in a way that makes its employees, partners and portfolio companies proud.

Tiger Global Management

AME Cloud Ventures focuses on seed to later stage companies building infrastructure and value chains around data. It specializes in technology-heavy companies gathering or creating unique data at every stage of the data stack — from infrastructure all the way to applications, mobile, and sensors.  It strives to find, fund, and support true entrepreneurs. The firm provides a unique and genuine set of resources to our founding teams, from strong operational and business experience to networks of amazing mentors and international partners, particularly in China. AME Cloud Ventures is the venture fund led by Jerry Yang, co-founder of Yahoo!

AME Cloud Ventures

1955 Capital invest in advanced technologies from the Americas and Europe to solve pressing problems in developing countries. China, India and other developing countries have survival-driven demands that can accelerate tech commercialization. Over the next decade, the developing world will face an onslaught of challenges in energy and environment, food safety and supply, and access to healthcare and education. In China, the fast-growing middle class and an aging population are putting pressure on Chinese leaders and businesses to find ways to solve them. Other developing countries are on the brink of facing similar issues. We believe these problems are so big, technology is the answer. 1955 Capital will invest in advanced technologies from the Americas and Europe that have the potential to solve these pressing problems. With a first close on $200 million completed, we are ready to help entrepreneurs and innovators gain direct access to these large and explosive end-markets to help accelerate technology commercialization, create jobs, and foster partnerships that will support their long-term growth and development. We will help bring nations closer together by matching the ingenuity of the West with the growing survival-driven demands of the East. The firm was founded in the Fall of 2015 by Andrew Chung, a former general partner at Khosla Ventures with extensive experience and success investing in these areas and commercializing technologies in China and beyond.

1955 Capital

Lenovo Capital and Incubator Group is an accelerator and venture capital firm.

Lenovo Capital and Incubator Group (LCIG)

UpHonest Capital is an early-stage, industry-agnostic venture capital firm that partners with companies from pre-seed stage to Series A. The firm invests in entrepreneurs and early-stage startups and then uses its resources to boost value creation through disruptive means.

UpHonest Capital

LYFE Capital is a pure play healthcare focused investment firm.  We believe that “Healthcare has no boundaries”, and that every new choice we made has the potential to advance healthcare and solve the unmet needs for everyone. LYFE Capital operates 5 global offices including our US headquarters in Menlo Park, California, our Asia headquarters in Singapore, as well as locations in Seoul, Tokyo and Shanghai. We leverage our expertise and global resources to invest in and create value for healthcare companies across the globe.  LYFE Capital’s investments span medical devices, therapeutics, diagnostics, and emerging sectors across North America and Asia.

LYFE Capital

Best-in-class investments mainly in the U.S. medical devices technology, as well as biotech, and mobile healthcare sectors through early sta

Shangbay Capital

HongShan is a VC firm focused on seed-stage, mid-stage, late-stage, and growth investments in the fintech sector. HongShan has offices in Hong Kong, Beijing, Shanghai, Guangzhou, Hangzhou, Suzhou, and Shenzhen. Over the past nine years, Sequoia Capital China has an impressive and diverse portfolio comprising about 300 dynamic companies that deliver high returns on investment using differentiated technologies and innovative business models, including Alibaba, VIPshop.com, Sina.com, Didi, JD.com, Ourpalm, Qihoo 360, Jumei, Momo, SINNET, Dianping.com, Meituan, Meilishuo, Toutiao, AutoNavi, Ganji.com, DJI, VanceInfo, Noah Private Wealth Management, Wanda Cinemas, Alibaba Pictures, Plateno Hotels Group, Deppon Logistics, ZTO Express, Beta Pharma, Snibe Diagnostic, BGI, WEGO, and Yuwell Medical.

HongShan

Founded in 2019, Ying Fund is a global venture capital and accelerator with a mission to finance and boost creative early-stage startups. We provide the tools needed to quickly scale and achieve series A round with the correct model, go to market strategy, and the right team. We are enthusiastic about consumer，entertainment, health and retail companies. To these partnerships we bring adaptable capital, deep domain knowledge, access to transformative industry connections and strategic and operational skill to our investments.

Ying Fund

Sunmed Capital is dedicated to promote innovation in medical devices by working closely with physicians, engineers, and other entrepreneurs.

Sunmed Capital

Noah Medical

Noah Medical is a manufacturer of medical robotic devices used to diagnose and treat patients in a variety of settings. The company's devices perform early diagnoses and treatments in advanced clinical settings, allowing hospitals to treat patients earlier and save lives while leaving only minor scars.

Noah Medical is a medical robotics company that has developed the Galaxy System, a robotic platform for navigated robotic bronchoscopy. The system is designed to improve the accuracy of locating and diagnosing lung nodules during bronchoscopy procedures. It features proprietary TiLT+ Technology, which integrates tomosynthesis and augmented fluoroscopy, providing real-time navigation and lesion updates during the procedure. The Galaxy System also includes a single-use disposable bronchoscope and a compact footprint, allowing easy integration into most bronchoscopy suites.

Pushing the envelope in MedTech with emerging technologies

Next-gen Medical Devices

Noah Medical on LinkedIn: #firstandonly #noahmedical #galaxysystem #lungcancer #bronchoscopy #iirab…

Noah Medical is a medical robotics company that has developed the Galaxy System, a robotic platform for navigated robotic bronchoscopy. The system is designed to improve the accuracy of locating and diagnosing lung nodules during bronchoscopy procedures. It features proprietary TiLT+ Technology, which integrates tomosynthesis and augmented fluoroscopy, providing real-time navigation and lesion updates during the procedure. The Galaxy System also includes a single-use disposable bronchoscope and a compact footprint, allowing easy integration into most bronchoscopy suites.The company received FDA clearance for the Galaxy System in March 2023, enabling its commercial use in the US. In the same year, Noah Medical initiated the first-in-human trials of the system at Macquarie University Hospital in Sydney, Australia.&nbsp;Key customers and partnershipsNoah Medical provides its solutions to the healthcare sector, targeting hospitals and specialized clinics across the US. As of January 2024, Noah Medical had reached a milestone of 500 commercial uses for the Galaxy System. Its Galaxy System was first used in the University of Chicago Medicine by Dr. Kyle Hogarth.

Convergent Dental, Inc. is a privately owned dental equipment and technology company. Its flagship product, Solea, is the only CO2 laser cleared by the FDA for all-tissue indications, delivering an anesthesia-free, blood-free, and suture-free experience for dentists and patients. Solea represents a breakthrough in dental laser technology, offering a distinct experience compared to traditional instruments or earlier laser treatments.
Solea is a novel 9.3-micron CO2 laser that nears the peak absorption of hydroxyapatite (enamel), enabling it to vaporize enamel with speed and precision. This unique wavelength, coupled with computer-controlled motors (galvos) that manipulate the beam thousands of times per second, allows dentists to perform procedures ranging from hard tissue to soft tissue with total control and efficiency.
A key feature of Solea is its variable-speed foot pedal, which lets dentists seamlessly transition from hard to soft tissue by adjusting the pressure applied. This intuitive design streamlines the learning curve for dentists accustomed to using a drill. Solea's three ergonomic handpieces – Contra-Angle, Straight, and Ultraguide – further enhance its versatility across various procedures.
Solea not only improves patient experiences but also offers practice benefits such as increased productivity, new patient flow, and efficiency gains. In October 2022, Convergent Dental received FDA clearance for Solea to aid in reducing mineral loss in dental enamel, protecting teeth against acid attack and caries development. This breakthrough application was commercially launched in November 2023 under the name Solea Protect.

Convergent Dental

Ossio is an orthopedic fixation technology company that has developed OSSIOfiber Intelligent Bone Regeneration Technology, a breakthrough implant material designed to securely fixate and fully integrate into the body's native anatomy without leaving any permanent hardware behind. This technology addresses the limitations of conventional metal and resorbable implants, combining unparalleled mechanical strength with natural bone healing.
Made from a proprietary mineral fiber matrix held together by a naturally degradable polymer, OSSIOfiber implants provide surgeons with a more biologically friendly way to restore patient stability and mobility. These implants are engineered to provide the strength required for functional fixation while allowing full integration into the native bone without adverse biological response.
Ossio's product portfolio includes compression screws, trimmable fixation nails, hammertoe fixation systems, suture anchors, and compression staples, all made with OSSIOfiber technology. These implants have received multiple FDA clearances since 2019, and the company has initiated commercialization of its products in the US. As of March 2022, over 6,000 implantations of OSSIOfiber products had been performed, demonstrating adoption of this innovative technology.
OSSIOfiber Intelligent Bone Regeneration Technology can address various surgical applications through the manufacturing of implant designs like nails, screws, staples, anchors, and plates. Ossio plans to pursue multiple applications in distal extremities, trauma, sports, reconstruction, pediatrics, and spine segments.
In February 2023, Ossio launched the world's first and only non-permanent compression staple made with OSSIOfiber technology, designed for predictable bone in-growth, regeneration, and replacement.

Ossio

Casana is a healthcare technology company that has developed the Heart Seat, an innovative toilet seat that enables effortless, integrated, and consistent in-home health monitoring. The Heart Seat is a replacement for a standard toilet seat and is designed to measure key clinical parameters such as heart rate, blood oxygen saturation (SpO2), and blood pressure.
In May 2023, Casana received FDA clearance for the Heart Seat to measure heart rate and SpO2 in adults aged 22 years and older, weighing between 90 to 350 pounds. The company plans to file for additional indications, including systolic and diastolic blood pressure, with the goal of launching the product in the market by the end of 2023.
The Heart Seat is equipped with sensors that passively capture health data whenever the seat is used, eliminating the need for user compliance or behavior changes. The data is automatically uploaded to the Casana Cloud, where it can be viewed by healthcare providers, enabling them to monitor patients' health trends and respond to changes in near real-time.
Casana's technology allows for the effortless collection of consistent and reliable data, assisting medical teams in monitoring chronic conditions beyond the hospital or physician's office. The company aims to unlock a new category in healthcare technologies that enables seamless, integrated, and continuous in-home health monitoring.
In January 2022, Casana was acquired by an undisclosed entity, further accelerating the commercialization of the Heart Seat.

Casana

Neurent Medical is a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, particularly chronic rhinitis. The company's flagship product is the NEUROMARK System, a device that received US Food and Drug Administration (FDA) 510(k) clearance in October 2021.
The NEUROMARK System is designed to gently apply controlled low-power radio frequency (RF) energy to target regions of the nasal cavity, disrupting the parasympathetic nerve signals that can trigger an inflammatory response. This alleviates chronic rhinitis symptoms such as persistent congestion, rhinorrhea (runny nose), swelling of the mucosal membrane, sneezing, and nasal itching. The system's unique flexible leaflet design and proprietary smart algorithms enable precise neurolysis (disruption) of the posterior nasal nerves (PNN) and accessory pathways, accommodating a range of patient anatomies while maintaining mucosal and vascular integrity.
Neurent Medical announced the limited market release of the NEUROMARK System in the US in February 2023, following the establishment of a new Category I Current Procedural Terminology (CPT) code by the American Medical Association (AMA) for PNN procedures, effective January 2024. The American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) also endorsed the PNN procedure in 2023.

Neurent Medical

Genetesis is a medical imaging company specializing in biomagnetic cardiac imaging solutions. It has developed CardioFlux, a flagship magnetocardiography (MCG) system that non-invasively identifies myocardial ischemia, a condition where blood flow to the heart muscle is reduced. The technology measures the magnetic fields generated by the heart's electrical activity to detect ischemia within minutes, without using pharmaceuticals or radiation. CardioFlux MCG is designed to provide advanced imaging while prioritizing patient comfort.
The company's solutions target the diagnosis of coronary microvascular disease (CMD), a condition that has been challenging to identify due to a lack of effective functional diagnostics. By offering an accurate and rapid test for CMD, Genetesis aims to address an unmet clinical need and enable timely management of the condition.
In April 2023, the US Food and Drug Administration (FDA) granted CardioFlux MCG Breakthrough Device designation for the non-invasive diagnosis of myocardial ischemia in patients suspected of having CMD.
Genetesis was founded in 2013 and is headquartered in Mason, Ohio. The company has received over USD 40 million in funding to date, including a USD 17.5 million Series C round in October 2022. In April 2020, TDK Ventures, the corporate venture capital arm of TDK Corporation, invested in Genetesis, providing access to TDK's expertise in areas like biomagnetic sensors and magnetic noise suppression.

Genetesis

Companies that develop diagnostic devices used in a hospital setting to identify a disease, condition, or injury, such as imaging systems and endoscopes

Companies that develop implantable medical devices designed to be surgically placed inside the human body, either temporarily or permanently, including devices such as pacemakers, artificial joints, stents, and cochlear implants

Companies that develop non-surgical devices that are used in a procedure or intervention to cure or relieve a patient from an illness or disease such as laser treatments, dental equipment, and wound care management

Companies that develop monitoring devices that are used in a hospital setting to measure patient vital signs and ensure patient well-being post-treatment, such as cardiac and respiratory monitoring systems

Providers of software that enhances the functionality of medical device hardware (diagnosis, treatment, and monitoring)

Companies that develop surgical devices involving invasive interventions (cutting into a patient's body tissues) to treat, cure, or relieve a patient of an illness or disease

Companies that develop devices to administer pharmaceutical substances into a patient's body, ensuring controlled release or targeted delivery, specifically for use in clinical settings to treat or manage medical conditions effectively

Providers of software that helps manage risks, ensure quality, and streamline audit processes during medical device development

IoT connects devices to EHR systems for precise patient diagnosis and treatment support

Devices are linked to software platforms that use digital technologies such as AI/ML and VR

Startups leverage AI/ML and deep learning to support patient diagnosis and early detection

Noah Medical

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless